ABSTRACT
Objective: The mental health issues of individuals with coronavirus disease 2019 (COVID-19) are currently widespread. Traditional Chinese exercise (Daoyin) plays an important role in relieving patients' psychological problems. This study aims to assess the efficacy of Daoyin in mitigating mental health issues among individuals diagnosed with COVID-19. Methods: PubMed, the Cochrane library, Embase, CNKI, Wanfang, VIP database, and SinoMed were searched from their inception to October 2023. Two researchers independently selected the eligible studies. The analysis and presentation of the findings were conducted using Review Manager 5.2 software. The data were analyzed using mean difference (MD), inverse variance, and 95% confidence intervals (CIs). Results: A total of 12 studies (N = 1291) were included in this study. The results showed that Daoyin can significantly reduce the scores of the Self-Rating Anxiety Scale (SAS: MD = -13.03, 95% CI -19.56 to -6.49, P<.49,yca Self-Rating Depression Scale (SDS: MD = -11.13, 95% CI -14.56 to -7.71, P<.71,sion Pittsburgh Sleep Quality Index (PSQI: MD = -2.00, 95% CI -5.43 to 1.43, P = 0.25), Hamilton Anxiety Scale (HAMA: MD = -2.42, 95% CI -5.25 to 0.41, P = 0.09), and Hamilton Depression Scale (HAMD: MD = -11.17, 95% CI -25.5 to 3.15, P = 0.13). Conclusion: In COVID-19 patients, Daoyin can alleviate feelings of anxiety and depression, as well as improve sleep quality. The use of Daoyin has no adverse effects and side effects and can reduce the cost of medication. Therefore, Daoyin can be widely promoted. Further research is warranted to analyze the effect of Daoyin on mental health. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/#recordDetails, identifier CRD42023391845.
ABSTRACT
Chronic obstructive pulmonary disease (COPD) has a high global morbidity and mortality and a severe disease burden, yet progress in treatment and prevention has been slow in recent decades. Early COPD has few symptoms and is severely underdiagnosed and undertreated; it is crucial to search for effective clues of early COPD and provide management interventions. By reviewing the definition, risk factors, diagnosis and management interventions, this study explores the disease evolution of early-stage COPD, which can help clinical practice to develop more effective preventive and therapeutic strategies for stopping or slowing down the natural progression of the disease, improving the long-term prognosis, and reducing the disease burden.
Subject(s)
Pulmonary Disease, Chronic Obstructive , Humans , Pulmonary Disease, Chronic Obstructive/therapy , Pulmonary Disease, Chronic Obstructive/drug therapy , Prognosis , Risk FactorsABSTRACT
Bronchial asthma (asthma) is a complex heterogeneous disease, with a high rate of missed diagnosis and misdiagnosis. Repeated attacks of bronchial asthma can cause complications such as chronic obstructive pulmonary disease, emphysema, and pulmonary heart disease. In recent years, mass-spectrometry-based metabolomics has developed rapidly. It can sensitively identify metabolic fluctuations and pathological changes in patients with asthma. By analyzing the molecules produced by various metabolic pathways,it can help us to find relevant biomarkers and provide a better method for early diagnosis and severity assessment of asthma. We reviewed and analyzed the literature of metabolomics technology in disease progression, early diagnosis and severity assessment, so as to provide reference for asthma research.